Clinical significance of serum ADP-ribosylation and NAD glycohydrolase activity in patients with colorectal cancer

Tumor Biology

Volumn 35, Issue 6, 2014, Pages 5575-5582

  Varol, Başak ^a   Coşkun, Özlem ^b   Karabulut, Senem ^c   Serin, Kürşat Rahmi ^d   Asoǧlu, Oktar ^d   Albeniz, Işil ^a   Taş, Faruk ^c   Nurten, Rüstem ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ÇANAKKALE ONSEKIZ MART UNIVERSITY   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

^d Liv Hospital   (Turkey)

Author keywords

ADP ribosylation; Colorectal cancer; NAD glycohydrolase activity; Serum

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSE; CARCINOEMBRYONIC ANTIGEN; NICOTINAMIDE ADENINE DINUCLEOTIDE NUCLEOSIDASE;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ADULT; ARTICLE; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PREOPERATIVE PERIOD; PRIORITY JOURNAL;

ADENOSINE DIPHOSPHATE; ADULT; AGED; AGED, 80 AND OVER; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NAD+ NUCLEOSIDASE; NEOPLASM STAGING;

EID: 84904721173     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1735-1     Document Type: Article

References (21)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Kulendran M, Stebbing JF, Marks CG, Rockall TA. Predictive and prognostic factors in colorectal cancer: a personalized approach. Cancers (Basel). 2011;3(2):1622-38.
3. Muto T, Bussey HJ,Morson BC. The evolution of cancer of the colon and rectum. Cancer. 1975;36(6):2251-70.
4. Ueda K, Hayaishi O. ADP-ribosylation. Annu Rev Biochem. 1985;54:73-100. (Pubitemid 15073642)
5. Moss J, Stanley SJ, Watkins PA, Vaughan M. ADP-ribosyltransferase activity of mono- and multi- (ADP-ribosylated) choleragen. J Biol Chem. 1980;255(16):7835-7.
6. Bektaş M, Nurten R, Ergen K, Bermek E. Endogenous ADP-ribosylation for eukaryotic elongation factor 2: evidence of two different sites and reactions. Cell Biochem Function. 2006;24(4):369-80. (Pubitemid 44065242)
7. Deaglio S, Aydin S, Vaisitti T, Bergui L, Malavasi F. CD38 at the junction between prognostic marker and therapeutic target. Trends Mol Med. 2008;4(5):210-8.
8. Malavasi F, Deaglio S, Funaro A, Ferrero E, Horenstein AL, Ortolan E, et al. Evolution and function of ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev. 2008;88(3):841-86.
9. Zocchi E, Franco L, Guida L, Benatti U, Bargellesi A, Malavasi F, et al. A single protein immunologically identified as CD38 displays NAD+ glycohydrolase, ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase activities at the outer surface of human erythrocytes. Biochem Biophys Res Commun. 1993;196(3):1459-65. (Pubitemid 23347613)
10. Jorcke D, Ziegler M, Herrero YA, Schweiger M. Enzymic, cysteine-specific ADP-ribosylation in bovine liver mitochondria. Biochem J. 1998;332:189-93. (Pubitemid 28239334)
11. Korkut C, Yalcintepe L, Kiremit-Korkut N, Uzun-Altinöz S, İşsever S, Gümüşel F, et al. Serum proteins with NAD+ glycohydrolase activity and anti-CD38 reactivity - elevated levels in serum of tumour patients. Cancer Lett. 1998;126(1):105-9. (Pubitemid 28142977)
12. Albeniz IU, Nurten R, Bermek E. ADP-ribosylation of serum proteins: evaluation as a potential tumor marker. Cancer Lett. 1996;108(2):239-45. (Pubitemid 26413529)
13. Nurten R, Üstündaǧ I, Sayhan N, Bermek E. ADP-ribosylation of human serum proteins promoted by endogenous NAD glycohydrolase activity. Biochem Biophysics Res Commun. 1994;200(1):450-8. (Pubitemid 24183629)
14. Kim H, Jacobson EL, Jacobson MK. Synthesis and degradation of cyclic ADP-ribose by NAD glycohydrolases. Science. 1993;261(5126):1330-3. (Pubitemid 24081171)
15. Malito E, Bursulaya B, Chen C, Lo Surdo P, Picchianti M, Balducci E, et al. Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197. Proc Natl Acad Sci U S A. 2012;109(14):5229-34.
16. Shia J, Klimstra DS, Bagci P, Basturk O, Adsay NV. TNM staging of colorectal carcinoma: issues and caveats. Semin Diagn Pathol. 2012;29(3):142-53.
17. Scarpa ES, Fabrizio G, Di Girolamo M. A role of intracellular mono-ADP-ribosylation in cancer biology. FEBS J. 2013;280(15):3551-62.
18. Masutani M, Fujimori H. Poly(ADP-ribosyl)ation in carcinogenesis. Mol Aspects Med. 2013;34(6):1202-16.
19. Yalcintepe L, Turker-Sener L, Sener A, Yetkin G, Tiryaki D, Bermek E. Changes in NAD/ADP-ribose metabolism in rectal cancer. Braz J Med Biol Res. 2005;38(3):361-5. (Pubitemid 40485175)
20. Albeniz IU, Nurten R, Bermek E. ADP-ribosylation of serum proteins: elevated levels in neoplastic cases due to altered NAD/ADP-ribose metabolism. Cancer Invest. 1997;15(3):217-23. (Pubitemid 27261661)
21. Mehrkhani F, Nasiri S, Donboli K, Meysamie A, Hedayat A. Prognostic factors in survival of colorectal cancer patients after surgery. Colorectal Dis. 2009;11(2):157-61.